Loading…
Improving Patient Access to Care and Treatment Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
93pct
354d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
Improving Patient Access to Care and Treatment Act This bill increases the number of days—from 14 to 60—within which a practitioner must administer certain narcotic drugs (e.g., buprenorphine) to a patient for maintenance or detoxification treatment (i.e., substance use disorder treatment) after receiving the drugs from a pharmacy.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2022 · fourth_quarter · Health Issues
HR 5950 and S 3257, the Improving Patient Access to Care and Treatment Act. Reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies
Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $5,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
HR 5950 and S 3257, the Improving Patient Access to Care and Treatment Act. Reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies
Client expense: Not reported · Firm income: Not reported
2021 · fourth_quarter · Health Issues
H.R. 586/ S. 1391 - STANDUP Act of 2021 H.R. 654 - Drug-Free Communities Pandemic Relief Act H.R. 925 - Data to Save Moms Act H.R. 1475/ S.1795 - Pursuing Equity in Mental Health Act H.R. 1667 / S.610 - Lorna Breen Health Care Provider Protection Act H.R. 2051 - Methamphetamine Response Act of 2021 H.R. 2163 / S. 464 - Safe Step Act H.R. 2255/ S. 1024 - Healthcare Workforce Resilience Act H.R. 2256/ S. 834 -Resident Physician Shortage Reduction Act H.R. 2364 - Synthetic Opioid Danger Awareness Act H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 H.R. 2503 - Social Determinants Accelerator Act of 2021 H.R. 3173/ S. 3018 - Improving Seniors' Timely Access to Care Act H.R 3441/S. 1438 - Substance Use Disorder Workforce Act/ Opioid Workforce Act H.R. 3407/ S. 411 - MOMMAs Act H.R. 3447 - Permanency for Audio-Only Telehealth Act H.R. 3541/ S. 1810 - Conrad State 30 and Physician Access Reauthorization Act H.R. 3753/S. 1962 - Parity Implementation Assistance Act H.R. 3894 - Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2021 H.R. 4026 - Social Determinants of Health Data Analysis Act of 2021 H.R. 4058/S. 2061 - Telemental Health Care Access Act H.R. 4194 - People's Response Act H.R. 4387 - Maternal Health Quality Improvement Act of 2021 H.R. 4406 - Supporting Medicaid in the U.S. Territories Act of 2021 H.R. 4770 - Evaluating Disparities and Outcomes of Telehealth (EDOT) Act of 2021 H.R. 4943 - Childrens Mental Health Infrastructure Act of 2021 H.R. 4944 - Helping Kids Cope Act of 2021 HR 5218 - Collaborate in an Orderly and Cohesive Manner Act H.R. 5235 - Student Mental Health Helpline Act of 2021 H.R. 5407 - Enhancing Mental Health and Suicide Prevention Through Campus Planning Act H.R. 5435/ S. 3427 - BRAIN Act of 2021/Neuroscience Center of Excellence Act of 2021 H.R. 5611/ S.1902 - Behavioral Health Crisis Services Expansion Act H.R. 5674/ S. 3061 - Medicare Mental Health Inpatient Equity Act H.R. 5837 - A bill to expand telehealth services relating to substance use disorder H.R.5950 - Improving Patient Access to Care and Treatment Act H.R. 6000 - Cures 2.0 Act H.R. 6020/ S. 3314 - Supporting Medicare Providers Act of 2021 H.R. 6202 - Telehealth Extension Act of 2021 S. 610 - Protecting Medicare and American Farmers from Sequester Cuts Act (No legislation) Implementation of No Surprises Act
Client expense: $83,505 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, Veterans Affairs, Dept of (VA)
2021 · fourth_quarter · Insurance
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2021 · fourth_quarter · Alcohol and Drug Abuse
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2021 · fourth_quarter · Pharmacy
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2021 · fourth_quarter · Health Issues
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2021 · fourth_quarter · Medicare/Medicaid
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2021 · fourth_quarter · Alcohol and Drug Abuse
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2021 · fourth_quarter · Insurance
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2021 · fourth_quarter · Medicare/Medicaid
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2021 · fourth_quarter · Health Issues
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2021 · fourth_quarter · Pharmacy
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
| Democratic |
| PA |
| Paul Tonko | Democratic | NY |
| Victoria Spartz | Republican | IN |